How should family spillover effects be measured in HTA?

A paper by Campbell et al. (2024) provides some guidance. The authors developed a series of recommendations based on literature review, expert interviews and an expert workshop in order to support consistent and transparent evaluation and use of validated family spillover effects in health technology assessments (HTA) and cost-effectiveness analyses (CEA). The expert panel consisted…

Read More

Let’s get moving on AI-discovered treatments

By STEVEN ZECOLA Recursion Pharmaceuticals announced results today for one its AI-discovered treatments. I was pleased to see the large, sustained reduction in polyps attributable to its treatment for Familial Adenomatous Polyposis.  Recursions’ oral medication will be viewed by the traditional scientific and regulatory community as “promising”. On the other hand, I was disappointed not…

Read More

Price Transparency Data Reveals the Real Story Behind Capital Women’s Care vs UnitedHealthcare Contract Battle (Part 1)

By JASON HINES On August 1, 2025, Capital Women’s Care (CWC), one of the largest OB/GYN practices in the Mid-Atlantic region went out-of-network with UnitedHealthcare, affecting tens of thousands of women across Maryland, Virginia, Pennsylvania, and Washington D.C. The contract dispute between Capital Women’s Care (CWC) and UnitedHealthcare offers a fascinating case study in how price transparency…

Read More